With REIMAGINE-4, we are comparing a potential new weight loss treatment called CagriSema to Tirzepatide (also known as Mounjaro®) in people with Type 2 Diabetes

Currently recruiting
HREC ethics approval number 2024.073

This is a randomised, open label research project where participants will receive either CagriSema or Mounjaro® tirzepatide. The study aims to determine if CagriSema offers improved glucose and weight control for people living with Type 2 diabetes.

Contact us to find out more about this research study, quoting reference number 2024.073

Study duration

Participants will receive either CagriSema or Mounjaro® tirzepatide and inject once weekly for up to 68 weeks.  

Who can take part

This trial might be right for you if you:

  • Are 18 years of age or older
  • Have a BMI of ≥ 30 kg/m2
  • Have been formally diagnosed with Type 2 Diabetes for more than 6 months, AND
  • Take metformin as part of your regular treatment for at least 3 months

 You may be ineligible to participate in this research project if you are currently taking insulin, or any weight loss medication

What's involved

  • Visits to the RMH
  • A weekly injection over 68 weeks
  • Medical assessments
  • Blood and urine tests, ECG, blood pressure, eye exams and weight measurements
  • Completing questionnaire
Person handling test tubes for research


All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.

This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.

Related services